On January 20,2026, a delegation led by Fang Guohong, General Manager of Strategic Clients at Danaher Group, including Senior Manager Li Yanqiu, Head of External Affairs for Central and South China Wang Longfei, External Affairs Manager Wang Hui, Life Science Platform Bioprocess Industry Development Expert Sun Chang, and Southern Region Manager of Cell Therapy Products Qu Yijie, visited Deep Harbour Cell Valley for in-depth exchanges. The delegation was warmly received by Professor Shi Yuanyuan, Chairman and General Manager of Cell Valley Group, Professor Wang Jianxun, Chief Scientist, Tang Xiaomeng, General Manager of Deep Harbour Cell Valley, Administrative Director Wei Zheng, and Han Shu, Director of the General Office. Both parties engaged in discussions on key topics including the construction of public service platforms in the biomedical field, innovative cooperation models, national market layout, and collaborative hospital operations. 

Accompanied by Professor Shi Yuanyuan, the Danaher Group delegation visited the industrialization layout platform and innovation achievement exhibition of Deep Harbour Cell Valley, gaining an in-depth understanding of the company's comprehensive chain layout in cell drug research and development, clinical translation, and industrial implementation.

At the symposium, Professor Shi Yuanyuan provided a detailed introduction to the business layout and development achievements of Cell Valley Group, with a focus on the company's core technological advantages, industrial collaboration outcomes, and global expansion. He highlighted that the company holds leading positions domestically and internationally in areas such as industrialized production of NK cells, exosome research and development, and viral vector technology, possessing multiple core patents and international certifications. Currently, the company has established in-depth partnerships with over 100 tertiary hospitals nationwide, comprehensively planning cutting-edge product lines including CAR-T, CAR-NK, NK cells, mesenchymal stem cells, and exosomes to meet diverse clinical needs in oncology, immunological diseases, and anti-aging. The company has achieved remarkable results in advancing the clinical application of frontier medical technologies.

Fang Guohong, General Manager of Strategic Clients at Danaher Group, elaborated on the group's business scope, core competencies, and global market scale. He stated that Danaher Group has been deeply engaged in the global life sciences sector for many years, continuously investing substantial resources to focus on cutting-edge biotechnologies and achieving multiple groundbreaking innovations. Additionally, the group possesses robust global supply chain integration capabilities, enabling it to provide efficient and stable product and service support to partners, thereby driving rapid advancements in the biomedical industry.

Professor Shi Yuanyuan stated that as a globally leading industrial M&A and integration enterprise, Danaher Group possesses top-tier technological solutions and a global resource network in the life sciences sector. The two parties have strong complementary advantages in technology R&D and industrial transformation. It is expected that both sides will leverage this exchange as an opportunity to deepen multi-dimensional cooperation, achieving resource sharing and mutual benefits.

Subsequently, both parties engaged in vigorous discussions on topics such as cooperation models, public service platforms, market layout, and hospital operations, reaching several key consensus points. These included exploring three major cooperation pathways: strategic supply chain collaboration, project collaboration, and overseas service expansion. The discussions aimed to accelerate the industrialization of clinical projects, achieve intensive resource utilization, and establish a benchmark for the coordinated development of the biomedical industry.